Radioimmunotherapy of ovarian cancer

Despite the advances in the management of ovarian cancer, the disease remains the leading cause of death from gynecological malignancies. As it generally remains confined to the peritoneal cavity, ovarian cancer is an attractive target for radioimmunotherapy via the intraperitoneal route of administration. Several clinical trials have been carried out investigating radiolabeled monoclonal antibodies and the results seem promising, especially in patients with small-volume residual disease after conventional therapy. Intraperitoneal radioimmunotherapy has yet to prove itself as an important part of the treatment of ovarian cancer.